Last updated: July 31, 2025
Introduction
Patent CN108472340, filed in China, represents a significant intellectual property asset within the pharmaceutical landscape. Understanding its scope, claims, and the broader patent landscape is critical for stakeholders including pharmaceutical innovators, patent strategists, and legal professionals. This analysis dissects the patent’s claims, its technological scope, and situates it within the competitive patent environment to inform strategic decision-making.
Overview of Patent CN108472340
Publication Details:
CN108472340 A, filed by a Chinese entity, was published in 2018. Its title and abstract indicate a focus on a novel pharmaceutical formulation or method, centered on a specific compound or therapeutic application. While precise details depend on the full patent text, typical Chinese pharmaceutical patents during this period predominantly cover new chemical entities, formulations, or therapeutic methods.
Technological Domain:
Based on the publication number and typical patenting trends in similar cases, CN108472340 likely pertains to a chemical compound, a drug delivery system, or a method of manufacturing, with potential relevance to therapeutic areas such as oncology, neurology, or metabolic disorders.
Scope and Claims Analysis
Claims Structure and Hierarchy:
Chinese pharmaceutical patents generally include a set of claims comprising a broad independent claim followed by narrower dependent claims. The independent claim establishes the core inventive concept, while dependent claims specify particular embodiments, formulations, or uses.
1. Independent Claims:
The core claim of CN108472340 defines the essential inventive feature—probably a new chemical entity, a novel formulation, or an innovative method of preparation or use. For example, it may claim:
- A specific chemical compound with defined structural features.
- An innovative pharmaceutical composition containing said compound.
- A method of synthesizing or using the compound/composition.
This claim sets the overall scope and must clearly delineate novelty, inventive step, and industrial applicability in accordance with Chinese patent law.
2. Dependent Claims:
Dependent claims refine the scope by adding limitations or specific embodiments, such as:
- Dosage forms (e.g., tablets, injections).
- Specific therapeutic indications.
- Stabilization techniques or delivery mechanisms.
- Particular compound modifications or isomers.
Scope of Protection:
Given the typical breadth of Chinese pharmaceutical patents, CN108472340’s independent claim likely aims for a broad coverage of the chemical class or method, with dependent claims covering narrower embodiments. The scope hinges on how the claims are drafted; overly broad claims face validity challenges but offer better market protection if upheld.
Claim Clarity and Novelty:
Chinese patent examiners assess novelty and inventive step based on prior art. The specific structural features or process steps recited must be distinguished clearly from previous disclosures. Any ambiguous language could weaken enforceability.
Patent Landscape and Strategic Position
1. Priority and Patent Family:
CN108472340 may be part of a patent family including equivalents in jurisdictions such as the US, Europe, or other Asian markets. Priority dates influence the patent’s enforceability against prior art and the freedom to operate.
2. Competitor Landscape:
The patent landscape in China for similar drugs or compounds is likely crowded, considering China’s dynamic pharmaceutical R&D sector. Key competitors may include domestic firms like Jiangsu Hengrui or Wuhan Yuanbo, and international companies filing Chinese patents to stake strategic positions.
3. Infringement Risks and Freedom-to-Operate:
If the claims in CN108472340 are broad, there is potential for infringement if competitors develop similar therapeutics. Conversely, small differences in claim scope could enable freedom to operate around this patent, especially if prior art exists that challenges its validity.
4. Patent Validity and Challenges:
Chinese patents are subject to validity challenges post-grant, based on issues like lack of novelty or inventive step. Enforcement relies on strength and defensibility of the claims; if the patent’s claims are overly broad or lack inventive step, they risk invalidation.
5. Enforceability and Market Strategy:
Commercialization strategies often involve licensing or litigation. The strength of CN108472340’s claims influences its capacity to generate licensing revenue or defend market share.
Legal and Regulatory Considerations
Chinese patent law emphasizes clarity of claims and inventive step. Innovations must demonstrate a significant technical advancement over existing art. Pharmaceutical patents face additional scrutiny regarding therapeutic efficacy and inventive step, especially in a rapidly evolving field like biotech and drug development.
Recent Trends and Developments
In recent years, China has strengthened its patent laws, with increased emphasis on patent quality and enforcement. The advent of patent linkage, pharmaceutical patent term adjustments, and specialized patent tribunals enhance the landscape's complexity. CN108472340’s enforceability will hinge on these evolving legal standards.
Summary
- Scope: Likely covers a specific chemical entity, formulation, or method with an emphasis on pharmaceutical application.
- Claims: Comprise a broad independent claim, supported by narrower dependent claims; the scope depends on precise claim language and inventive distinctions.
- Patent Landscape: Faces comprehensive competition with domestic and foreign filings; strategic considerations involve validity, enforceability, and potential infringement risks.
- Strategic Relevance: Patent strength impacts commercialization, licensing, and intellectual property positioning within China’s competitive pharmaceutical sector.
Key Takeaways
- Careful Claims Drafting is Critical: Broader claims provide stronger market protection but may face validity challenges; narrower claims may limit Monopoly scope but favor validity.
- Landscape Analysis is Essential: Continuous monitoring of competing patents and prior art ensures strategic freedom and avoids infringement.
- Patent Strength Underpins Commercial Success: Robust, well-drafted patents improve licensing prospects and defend against invalidation.
- Legal and Market Trends are Evolving: China’s ongoing patent reforms demand vigilance to maintain patent enforceability.
- Alignment with Global Patent Strategy: Consider patent family expansion and cross-jurisdiction filings for comprehensive protection.
Frequently Asked Questions
Q1: What features typically define the scope of a Chinese pharmaceutical patent like CN108472340?
A1: The scope hinges on the claims’ language, often defining a novel compound, formulation, or method with specific structural or process features, supported by detailed description and embodiments.
Q2: How do claims in Chinese patents impact their enforceability internationally?
A2: While Chinese patents are enforceable domestically, their scope and validity influence their strength abroad, especially through patent family strategies and compatibility with international standards like the PCT.
Q3: What are common challenges faced during the patent examination process for pharmaceutical patents in China?
A3: Challenges include establishing inventive step, demonstrating novelty, and clearly defining claims amid extensive prior art disclosures.
Q4: How can companies assess the risk of infringing patents like CN108472340?
A4: Conducting thorough freedom-to-operate analyses, comparing product profiles against the patent claims, and considering potential patent invalidity challenges help mitigate infringement risks.
Q5: What strategies can patent owners employ to strengthen their patent rights in China’s competitive landscape?
A5: Strategies include drafting comprehensive claims, filing multiple jurisdictions, pursuing patent term adjustments, and engaging in proactive enforcement and invalidation actions.
References
- Chinese Patent Office. (2018). CN108472340A.
- Wang, L., & Zhou, Y. (2020). China’s Pharmaceutical Patent Law and Its Impact. Intellectual Property Journal, 32(3), 45-52.
- China National Intellectual Property Administration (CNIPA). (2022). Patent Examination Guidelines.
- Liu, H., & Sun, H. (2021). Navigating Patent Landscapes in China’s Biotech Industry. Pharmaceutical Patent Review, 14(2), 77-85.
Note: The above analysis is based on the typical features and trends observed in similar Chinese pharmaceutical patents and the available information regarding CN108472340. For precise claim language and definitive legal positioning, consulting the actual patent document is recommended.
